阿加曲班与低分子肝素钠在床旁血液滤过治疗中的疗效观察

发布时间：2018-11-02 17:43

【摘要】：本研究旨在探讨阿加曲班在床旁血液滤过治疗中的抗凝效果及安全性。选取2015年8月~2016年8月在我院行床旁血液滤过治疗的166例患者,其中采用阿加曲班进行抗凝治疗的患者62例作为观察组,采用低分子肝素钠进行抗凝治疗的患者104例作为对照组。分别于治疗前、第1次、第5次治疗结束后检测两组患者的血红蛋白(Hb)、血小板计数(PLT)及凝血酶原时间(APTT);抗凝效果观察指标包括:滤器残余血量、滤器跨膜压、滤器使用寿命,并同时观察对比两组的出血风险。本研究结果显示:治疗前观察组患者的血浆APTT、Hb、PLT水平比较差异无统计学意义(p0.05);第1次和第5次治疗结束后,两组患者的血浆APTT水平均较治疗前明显升高,血浆Hb、PLT水平明显降低,差异具有统计学意义(p0.05)。第5次治疗后和第1次治疗后比较,观察组患者的血浆APTT、Hb、PLT水平比较差异无统计学意义(p0.05);而对照组患者血浆APTT水平明显升高,PLT水平较治疗前明显降低,差异具有统计学意义(p0.05)。治疗结束后两组患者的滤器残余血量、滤器跨膜压、滤器使用寿命比较差异无统计学意义(p0.05),两组均无明显的出血事件发生。本研究认为床旁血液滤过治疗时采用阿加曲班进行抗凝治疗,抗凝效果及安全性良好,尤其适用于有出血风险的患者。
[Abstract]:The aim of this study was to investigate the anticoagulant effect and safety of Agatripine in bedside hemofiltration therapy. From August 2015 to August 2016, 166 patients underwent bedside hemofiltration therapy in our hospital. Among them, 62 patients were treated with Agatreban as observation group. 104 patients treated with low molecular weight heparin sodium anticoagulant were used as control group. Hemoglobin (Hb), platelet count (PLT) and prothrombin time (APTT);) were measured before, first and fifth time after treatment. The parameters of anticoagulant effect included: filter residual blood volume, filter transmembrane pressure, filter service life, and the bleeding risk of the two groups were observed and compared at the same time. The results showed that there was no significant difference in plasma APTT,Hb,PLT levels between the two groups before treatment (p0. 05). At the end of the first and fifth treatment, the plasma APTT level was significantly higher and the plasma Hb,PLT level was significantly lower in the two groups than before (p0.05). There was no significant difference in plasma APTT,Hb,PLT levels between the observation group and the observation group after the fifth treatment and the first treatment (p0.05). In the control group, the plasma APTT level was significantly higher and the PLT level was significantly lower than that before treatment (p0.05). There was no significant difference in filter residual blood volume, filter transmembrane pressure and filter service life between the two groups (p0.05). There was no significant bleeding event in the two groups. In this study, it is concluded that the anticoagulant effect and safety of Agatripine in bedside hemofiltration therapy are good, especially for patients at risk of bleeding.
【作者单位】：河北大学附属医院;
【基金】：河北大学附属医院资助
【分类号】：R459.5

【相似文献】